Patient interest and willingness-to-pay (WTP) out-of-pocket (OOP) for comprehensive tumor genetic profiling (CGP).

1545 Background: CGP via multiplex gene panels has emerged as a novel technology to identify mutations in pathologically relevant cancer genes for therapy targeting. While CGP is anticipated to alter the course of standard cancer care, its current clinical role remains ill-defined, and thus its perceived value for patients is unclear. In an effort to understand patient awareness and perceived value of CGP, we explored interest and WTP OOP for CGP among cancer patients receiving active treatment. Methods: Fox Chase patients were recruited to complete a 20 min survey. In addition to assessing demographics, cancer stage/treatment, and financial items (income, health insurance, co-pays), we queried awareness of CGP, and interest in CGP to guide therapy using items adapted from previous research by our group. We specifically assessed interest in CGP only if covered by insurance vs interest conditional on paying an OOP cost: ( $1000). All p-values are significant at α = 0.05 using two-sided ...